Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17
Objectives The aim of this study was to assess the vitamin D status in treatment-naïve SLE patients and its association with clinical and laboratory markers of disease activity, including serum levels of IL-17 and IL-23. Methods Fifty-seven treatment-naïve SLE patients along with 42 matched controls were included. SLEDAI score was used to estimate disease activity. Serum levels of 25(OH) D, IL-17 and IL-23 were measured. Results The median level of 25(OH) D in SLE patients (40.8; 4–70 ng/ml) was significantly lower than in the controls (47; 25–93 ng/ml) (P = 0.001). A total of 38.6% of SLE cases had 25 (OH) D levels < 30 ng/ml (hypovitaminosis D) vs. 4.8% of the controls (P < 0.0001). Apart from thrombocytopenia, vitamin D was not associated with clinical signs of SLE. There were negative correlations between serum 25(OH) D and serum levels of IL-17, IL-23 and ANA (rho = −0.5, −0.8, −0.5, P ≤ 0.05) in SLE patients. Conclusion Hypovitaminosis D is prevalent in treatment naïve SLE patients. It contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17; thus they may trigger the inflammatory process in SLE..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Lupus - 26(2017), 9, Seite 917-926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shahin, D [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1177/0961203316682095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1996319396 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1996319396 | ||
| 003 | DE-627 | ||
| 005 | 20230507225428.0 | ||
| 007 | tu | ||
| 008 | 170901s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0961203316682095 |2 doi | |
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1996319396 | ||
| 035 | |a (DE-599)GBVOLC1996319396 | ||
| 035 | |a (PRQ)s743-d65ccba3208d1a2a22d6d12436234f12b0747eaa52d1af640bf24ca80c8b6b960 | ||
| 035 | |a (KEY)0208401520170000026000900917serum25ohvitamindlevelintreatmentnavesystemiclupus | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.78 |2 bkl | ||
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Shahin, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17 |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Objectives The aim of this study was to assess the vitamin D status in treatment-naïve SLE patients and its association with clinical and laboratory markers of disease activity, including serum levels of IL-17 and IL-23. Methods Fifty-seven treatment-naïve SLE patients along with 42 matched controls were included. SLEDAI score was used to estimate disease activity. Serum levels of 25(OH) D, IL-17 and IL-23 were measured. Results The median level of 25(OH) D in SLE patients (40.8; 4–70 ng/ml) was significantly lower than in the controls (47; 25–93 ng/ml) (P = 0.001). A total of 38.6% of SLE cases had 25 (OH) D levels < 30 ng/ml (hypovitaminosis D) vs. 4.8% of the controls (P < 0.0001). Apart from thrombocytopenia, vitamin D was not associated with clinical signs of SLE. There were negative correlations between serum 25(OH) D and serum levels of IL-17, IL-23 and ANA (rho = −0.5, −0.8, −0.5, P ≤ 0.05) in SLE patients. Conclusion Hypovitaminosis D is prevalent in treatment naïve SLE patients. It contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17; thus they may trigger the inflammatory process in SLE. | ||
| 540 | |a Nutzungsrecht: © The Author(s) 2016 | ||
| 700 | 1 | |a El-Farahaty, R M |4 oth | |
| 700 | 1 | |a Houssen, M E |4 oth | |
| 700 | 1 | |a Machaly, S A |4 oth | |
| 700 | 1 | |a Sallam, M |4 oth | |
| 700 | 1 | |a ElSaid, T O |4 oth | |
| 700 | 1 | |a Neseem, N O |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Lupus |d London : Sage, 1991 |g 26(2017), 9, Seite 917-926 |w (DE-627)171120957 |w (DE-600)1154407-7 |w (DE-576)048511234 |x 0961-2033 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2017 |g number:9 |g pages:917-926 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1177/0961203316682095 |3 Volltext |
| 856 | 4 | 2 | |u http://journals.sagepub.com/doi/full/10.1177/0961203316682095 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.78 |q AVZ |
| 936 | b | k | |a 44.83 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2017 |e 9 |h 917-926 | ||